The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
7th European CAR T-cell Meeting congress coverage
Stay up to date with the latest developments in acute lymphoblastic leukemia with our live social media coverage from the 7th European CAR T-cell Meeting, February 6–8, 2025, Strasbourg, France
CONGRESS | #CART25 | PRESENTATION
— ALL Hub (@ALL_Hub_) February 6, 2025
Peter Bader, @goetheuni discusses key data from real-world studies of tisagenlecleucel in pediatric patients with ALL. Results suggest that disease burden and early relapses post allo-HSCT impact survival outcomes.#leusm #ALLsm #MedicalCongress pic.twitter.com/xhpQUEQ7yW
CONGRESS | #CART25 | PRESENTATION@drclaireroddie @ucl @uclcancer @uclh discusses CAR T-cell therapies for adult patients with ALL. They highlight results from the FELIX trial of obe-cel in adult patients with R/R B-ALL, and discuss factors associated with survival outcomes.… pic.twitter.com/s80eOKm6gB
— ALL Hub (@ALL_Hub_) February 6, 2025
CONGRESS | #CART25 | PRESENTATION
— ALL Hub (@ALL_Hub_) February 8, 2025
Valentin Ortiz-Maldonado @ValentinOrtizMD @hospitalclinic presents initial results from the CART19-BE-02 trial of varnimcabtagene autoleucel in adult patients with R/R B-ALL. The primary endpoint was met, with an MRD-negative CR rate at Day +28… pic.twitter.com/fkbJAX7KG8
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content